Back to results

Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults

Primary Purpose

Malaria, Plasmodium Vivax

Status

Terminated

Phase

Phase 2

Locations

Thailand

Study Type

Interventional

Intervention

Tafenoquine

Chloroquine + Primaquine

tafenoquine

Chloroquine + Primaquine

About this trial

This is an interventional treatment trial for Malaria focused on measuring malaria, Plasmodium vivax, adults, treatment, tafenoquine

Eligibility Criteria

20 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Positive smear for P. vivax.
Parasite density > 500 and < 200,000/μl
Age: 20-60 years old
Willing to sign consent form
Willing to be hospitalized for 29 days and remain in a malaria free region for 60 days thereafter for follow-up.
A female is eligible to enter and participate in this study if she is of:

a non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who is post-menopausal or, b child-bearing potential, has a negative pregnancy (urine or serum) test at screen, and agrees to comply with recognized contraceptive methods during the treatment stage of the study and for a period of 12 weeks after stopping study drug. Recognized contraceptive methods include, abstinence, implants of levonorgestrel, injectable progestogen, or appropriate double barrier methods using licensed contraceptives such as diaphragm and condom (by the partner) or intrauterine device and condom. The use of oral/patch contraceptives during the study is not considered sufficient contraceptive protection.

Exclusion Criteria:

Mixed malaria infections by Field's stain.
Female subjects who are pregnant, lactating or unwilling/unable to comply with recognized contraceptive methods during the treatment stage of the study and for a period of 12 weeks after stopping study drug.
Symptoms of severe vomiting (no food or inability to take food during the previous 8 hours).
Demonstrated glucose-6-phosphate dehydrogenase deficiency.
Subject has taken other anti-malarials (mefloquine, primaquine, chloroquine) within the past 30 days by history
Clinically significant illness (intercurrent illness e.g. pneumonia, pre-existing condition e.g. renal disease, malignancy or conditions that may affect absorption of study medication e.g. severe diarrhea or any signs of malnutrition as defined clinically).
Clinically significant abnormal laboratory values as determined by history, physical examination or routine blood chemistries and hematology values (laboratory guideline values for exclusion are hemoglobin <7 gm/dL, platelets < 50,000/μl, White Blood Cell count (WBC) < 2000/μl, serum creatinine >2.0mg/dL, or ALT or AST more than 3 times the upper limit of normal for age.
History of allergy to chloroquine, mefloquine, tafenoquine, primaquine or any other 8-aminoquinolines.
Subject has taken another investigational drug within 30 days or 5 half lives (whichever is longer), of study start.
History of previous eye surgery or have evidence of corneal or retinal abnormalities identified in baseline ophthalmological examination.
Subjects taking concomitant medications likely to affect renal or ophthalmic function or that are known to be metabolized primarily by the cytochrome P450 isoforms 3A4/5 and 2C9 and whose therapeutic effect occurs within a narrow plasma concentration range (e.g. warfarin, ketoconazole).
Subjects whom, after examination by the study ophthalmologist, are judged to be at risk for acute angle closure glaucoma.
Females who are pre-menarchal.

Sites / Locations

Bangkok Hospital for Tropical Diseases/Mahidol University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Experimental

Active Comparator

Arm Label

Cohort 1 Tafenoquine

Cohort 1-Chloroquine

Cohort 2 Tafenoquine

Cohort 2 Chloroquine

Arm Description

Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.

Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.

Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.

Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.

Outcomes

Primary Outcome Measures

Adequate Clinical Response (ACR) of Tafenoquine: 28 Day Cure Rate

A subject will be considered a success (cure) if they have an Adequate Clinical Response (ACR). Tafenoquine was efficacious if the lower bound of the two-sided 90% confidence interval for the day 28 cure rate was not less than 85%

Secondary Outcome Measures

Number of Subjects Without Relapse of P. Vivax

Number of subjects without relapse of P. vivax at 2, 3 and 4 months - Blood smears were obtained at Days 28, 60, 90 and 120 to confirm the continued absence of P. vivax parasitemia

Safety and Tolerability of Tafenoquine as Defined by Most Common Adverse Events (AEs)

To evaluate the safety and tolerability of the tafenoquine dosing regimens as defined by the most common AE's overall, occurring in >10% of subjects in either treatment group

Parasite and Gametocyte Clearance Time (PCT and GCT)

Serial blood smears to detect the presence of P. vivax parasites and gametocytes, conducted every 12 hours up to and including day 7, until blood smear became negative were utilized to determine the time to clearance. PCT and GCT were considered cleared if 2 consecutive blood smears were negative.

Full Information

NCT ID

NCT01290601

First Posted

February 3, 2011

Last Updated

January 29, 2018

Sponsor

U.S. Army Medical Research and Development Command

Collaborators

GlaxoSmithKline

1. Study Identification

Unique Protocol Identification Number

NCT01290601

Brief Title

Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults

Official Title

A Randomized, Active-control, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults

Study Type

Interventional

2. Study Status

Record Verification Date

January 2018

Overall Recruitment Status

Terminated

Why Stopped

Failure to meet pre-specified endpoint for the day 28 cure rate

Study Start Date

September 15, 2003 (undefined)

Primary Completion Date

January 10, 2005 (Actual)

Study Completion Date

January 10, 2005 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

U.S. Army Medical Research and Development Command

Collaborators

GlaxoSmithKline

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This Phase II study is designed to determine whether a single 600 mg dose or 400mg/day for 3 days of tafenoquine is efficacious, and well tolerated for clearing P. vivax malaria infection (blood schizontocidal and gametocytocidal activity) and preventing P. vivax relapse (hypnozoite eradication). It will also further establish the safety and tolerability of these doses of tafenoquine.

Detailed Description

This was a randomized, active-control, double-blind, double-dummy study to be conducted in 2 sequential cohorts. Cohort 1 was randomized 2:1 to receive tafenoquine, 400mg/day for 3 days, or the standard blood schizontocidal dosing regimen of chloroquine (1000mg for 2 days followed by 500mg for 1 day) followed by a standard hypnozoite eradication dosing regimen for primaquine (15mg base per day for 14 days). Cohort 2 was to be randomized 2:1 to receive a single 600mg dose of tafenoquine or the standard blood schizontocidal dosing regimen of chloroquine (1000mg for 2 days followed by 500mg for 1 day) followed by a standard hypnozoite eradication dosing regimen for primaquine (15mg base per day for 14 days). A planned interim analysis was performed after all subjects in Cohort 1 had completed the day 28 assessment and an Independent Data Monitoring Committee (IDMC) convened to evaluate the efficacy and safety of the tafenoquine dosing regimen (400mg once per day for 3 days) used in Cohort 1. Only if the results from Cohort 1 met pre-defined efficacy and safety criteria was enrollment to begin for Cohort 2. The efficacy criterion for achieving the primary endpoint was that the lower limit of the one-sided 95% confidence interval was no less than 85%, and for safety that a review of trends in all AEs, tolerability, medical observations, methemoglobin and other lab data for all subjects indicated the dose was well tolerated. During the IDMC review it was determined that Cohort 1 failed to meet the pre-specified endpoint for the day 28 cure rate and therefore Cohort 2 should not be initiated and follow-up in Cohort 1 should be completed according to protocol. Following last subject last visit for Cohort 1 the study was terminated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Malaria, Plasmodium Vivax

Keywords

malaria, Plasmodium vivax, adults, treatment, tafenoquine

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Sequential Assignment

Model Description

Only if Cohort 1 met specified endpoint criteria would Cohort 2 begin enrollment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

70 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Cohort 1 Tafenoquine

Arm Type

Experimental

Arm Description

Arm Title

Cohort 1-Chloroquine

Arm Type

Active Comparator

Arm Description

Arm Title

Cohort 2 Tafenoquine

Arm Type

Experimental

Arm Description

Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.

Arm Title

Cohort 2 Chloroquine

Arm Type

Active Comparator

Arm Description

Intervention Type

Drug

Intervention Name(s)

Tafenoquine

Intervention Description

Intervention Type

Drug

Intervention Name(s)

Chloroquine + Primaquine

Intervention Description

Intervention Type

Drug

Intervention Name(s)

tafenoquine

Intervention Description

Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.

Intervention Type

Drug

Intervention Name(s)

Chloroquine + Primaquine

Intervention Description

Primary Outcome Measure Information:

Title

Adequate Clinical Response (ACR) of Tafenoquine: 28 Day Cure Rate

Description

Time Frame

28 Days

Secondary Outcome Measure Information:

Title

Number of Subjects Without Relapse of P. Vivax

Description

Number of subjects without relapse of P. vivax at 2, 3 and 4 months - Blood smears were obtained at Days 28, 60, 90 and 120 to confirm the continued absence of P. vivax parasitemia

Time Frame

Day 28, Months 2, 3 and 4

Title

Safety and Tolerability of Tafenoquine as Defined by Most Common Adverse Events (AEs)

Description

To evaluate the safety and tolerability of the tafenoquine dosing regimens as defined by the most common AE's overall, occurring in >10% of subjects in either treatment group

Time Frame

90 Days

Title

Parasite and Gametocyte Clearance Time (PCT and GCT)

Description

Time Frame

up to day 7 after baseline smear

Other Pre-specified Outcome Measures:

Title

Fever Clearance Time (FCT)

Description

Measure of body temperature every 12 hours through day 7 was used to determine the time (to nearest 12 hours) from initiation of treatment until subjects temperature decreased to 37.2C and remained at or below that level for a minimum of 24 hours.

Time Frame

through day 7

10. Eligibility

Sex

All

Minimum Age & Unit of Time

20 Years

Maximum Age & Unit of Time

60 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Positive smear for P. vivax. Parasite density > 500 and < 200,000/μl Age: 20-60 years old Willing to sign consent form Willing to be hospitalized for 29 days and remain in a malaria free region for 60 days thereafter for follow-up. A female is eligible to enter and participate in this study if she is of: a non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who is post-menopausal or, b child-bearing potential, has a negative pregnancy (urine or serum) test at screen, and agrees to comply with recognized contraceptive methods during the treatment stage of the study and for a period of 12 weeks after stopping study drug. Recognized contraceptive methods include, abstinence, implants of levonorgestrel, injectable progestogen, or appropriate double barrier methods using licensed contraceptives such as diaphragm and condom (by the partner) or intrauterine device and condom. The use of oral/patch contraceptives during the study is not considered sufficient contraceptive protection. Exclusion Criteria: Mixed malaria infections by Field's stain. Female subjects who are pregnant, lactating or unwilling/unable to comply with recognized contraceptive methods during the treatment stage of the study and for a period of 12 weeks after stopping study drug. Symptoms of severe vomiting (no food or inability to take food during the previous 8 hours). Demonstrated glucose-6-phosphate dehydrogenase deficiency. Subject has taken other anti-malarials (mefloquine, primaquine, chloroquine) within the past 30 days by history Clinically significant illness (intercurrent illness e.g. pneumonia, pre-existing condition e.g. renal disease, malignancy or conditions that may affect absorption of study medication e.g. severe diarrhea or any signs of malnutrition as defined clinically). Clinically significant abnormal laboratory values as determined by history, physical examination or routine blood chemistries and hematology values (laboratory guideline values for exclusion are hemoglobin <7 gm/dL, platelets < 50,000/μl, White Blood Cell count (WBC) < 2000/μl, serum creatinine >2.0mg/dL, or ALT or AST more than 3 times the upper limit of normal for age. History of allergy to chloroquine, mefloquine, tafenoquine, primaquine or any other 8-aminoquinolines. Subject has taken another investigational drug within 30 days or 5 half lives (whichever is longer), of study start. History of previous eye surgery or have evidence of corneal or retinal abnormalities identified in baseline ophthalmological examination. Subjects taking concomitant medications likely to affect renal or ophthalmic function or that are known to be metabolized primarily by the cytochrome P450 isoforms 3A4/5 and 2C9 and whose therapeutic effect occurs within a narrow plasma concentration range (e.g. warfarin, ketoconazole). Subjects whom, after examination by the study ophthalmologist, are judged to be at risk for acute angle closure glaucoma. Females who are pre-menarchal.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Sornchai Looaree Suwan, MD

Organizational Affiliation

Mahidol University

Official's Role

Principal Investigator

Facility Information:

Facility Name

Bangkok Hospital for Tropical Diseases/Mahidol University

City

Bangkok

ZIP/Postal Code

10400

Country

Thailand

12. IPD Sharing Statement

Plan to Share IPD

Citations:

PubMed Identifier

30269312

Citation

Warrasak S, Euswas A, Fukuda MM, Ittiverakul M, Miller RS, Krudsood S, Ohrt C. Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. Int Ophthalmol. 2019 Aug;39(8):1767-1782. doi: 10.1007/s10792-018-1003-2. Epub 2018 Sep 29.

Results Reference

derived

PubMed Identifier

29121061

Citation

Fukuda MM, Krudsood S, Mohamed K, Green JA, Warrasak S, Noedl H, Euswas A, Ittiverakul M, Buathong N, Sriwichai S, Miller RS, Ohrt C. A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria. PLoS One. 2017 Nov 9;12(11):e0187376. doi: 10.1371/journal.pone.0187376. eCollection 2017.

Results Reference

derived

Learn more about this trial

Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults

We'll reach out to this number within 24 hrs